Imagine if instead of taking ten different tests to find out what you are allergic to, you could find every single trigger in one go. This technology uses tiny color-coded beads that act like magnets for specific allergens in your blood. When a match is found, it lights up, allowing doctors to see up to 1,000 different allergies from a single drop of blood.
Current allergy diagnosis is slow and expensive because patients must undergo multiple separate tests for different allergens. This is inefficient given that 80% of allergy sufferers have cross-allergies.
A diagnostic kit called NexDiag using bio-functionalised micro-pearls and GFP reporters to detect up to 1,000 allergens in one blood sample.
If you are a diagnostic lab dealing with the high cost and time of running multiple individual allergy tests — this project developed a kit that assays up to 1,000 allergens with one blood sample. This can lead to a 10-20x reduction in diagnostic time and costs.
If you are a research firm dealing with the need for precise quantitative data on allergen-specific IgE — this project developed a system with 1nM sensitivity. This allows for a 3 log dynamic scale to better define patient treatments.
If you are a food producer dealing with the risk of undetected allergens in products — this project developed a technology that can be extended to detect antigens and toxic agents in food. This ensures higher safety standards through high-multiplexing detection.
The technology allows for the assay of 500 to 1,000 allergens using only one drop of blood. This is expected to result in a 10-20x reduction in associated costs and time.
Yes, the objective states it can be extended to serology tests for infectious agents, cancer markers, and environmental toxins in humans and animals.
Based on available project data, the specific IP and licensing terms are not disclosed, though the project is led by the SME NEXDOT.
The system offers a sensitivity of 1nM and a 3 log dynamic scale for quantitative measurement of individual allergens.
The project period runs from 2023-05-01 to 2026-07-31, indicating the development phase is ongoing until mid-2026.
The project is managed by a single-partner consortium consisting of one French SME, NEXDOT. This 100% industry-led structure suggests a strong focus on commercialization and rapid market entry rather than academic research.
Contact NEXDOT in France for partnership opportunities regarding the NexDiag kit.
Contact us to explore licensing opportunities for high-multiplexed diagnostic sensors.
